Taro Pharmaceutical Industries Ltd.  

(Public, NYSE:TARO)   Watch this stock  
Find more results for Taro Pharmaceutical Industries Ltd
+1.87 (1.42%)
Feb 12 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 130.37 - 134.02
52 week 122.99 - 162.81
Open 133.84
Vol / Avg. 133,258.00/104,823.00
Mkt cap 5.81B
P/E 10.29
Div/yield     -
EPS 13.01
Shares 42.83M
Beta 0.80
Inst. own 14%
Feb 10, 2016
Q3 2016 Taro Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 62.98% 56.27%
Operating margin 58.94% 61.14%
EBITD margin - 62.49%
Return on average assets 29.03% 32.14%
Return on average equity 34.15% 39.97%
Employees 1,339 -
CDP Score - -


14 Hakitor Street, Haifa Bay P.O. Box 10347
HAIFA, 26110
+972-4-8475700 (Phone)
+972-4-8727165 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company develops, manufactures and markets prescription (Rx) and over-the-counter (OTC) pharmaceutical products, primarily in the United States, Canada and Israel. Taro also develops and manufactures active pharmaceutical ingredients (APIs), primarily for use in its finished dosage form products. The Company's primary areas of focus include semi-solids formulations, such as creams and ointments, and other dosage forms, such as liquids, capsules and tablets, primarily in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. Taro's owned product brands include Rokacet, Topicort, Etopan, Lustra and Ovide. Its other generic products include acetazolamide, amiodarone hydrochloride, ammonium lactate, calcipotriene, carbamazepine, cetirizine hydrochloride, ciclopirox olamine, clindamycin, clobetasol propionate and clomipramine hydrochloride.

Officers and directors

Dilip Shantilal Shanghvi Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Kalyanasundaram Subramanian Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Michael H. Kalb CPA Interim Chief Financial Officer, Group Vice President, Chief Accounting Officer; Chief Financial Officer of Taro U.S.A.
Age: 43
Bio & Compensation  - Reuters
Stephen Manzano Esq. Interim General Counsel, Vice President of Corporate Compliance
Age: 48
Bio & Compensation  - Reuters
Sunil Mehta Group Vice President, General Manager - Canadian operations
Age: 53
Bio & Compensation  - Reuters
Brant Schofield Vice President - Sales & Marketing, TPHA, U.S.A.
Age: 47
Bio & Compensation  - Reuters
Michele Visosky Vice President - Human Resources, U.S.A.
Age: 47
Bio & Compensation  - Reuters
Mariana Bacalu Group Vice President - Quality Affairs
Age: 61
Bio & Compensation  - Reuters
Michael Teiler Group Vice President - Portfolio Management
Age: 50
Bio & Compensation  - Reuters
Rami Zajicek Esq. Group Vice President, Haifa Site Manager
Age: 49
Bio & Compensation  - Reuters